What Factors Predict Conversion to THA After Arthroscopy?

• DOI: 10.1007/s11999-017-5437-z
• Publication Date: 2017-07-07T14:18:20Z
• Authors: John M. Redmond; Asheesh Gupta; Kevin Dunne; Ammar Humayun; Leslie C. Yuen; Benjamin G. Domb
• Keywords: Hip Arthroscopy

Failure of hip preservation to alleviate symptoms potentially subjects the patient reoperation or conversion surgery THA, adding recovery time, risk, and cost. A risk calculator using an algorithm that can predict likelihood a who undergoes arthroscopic will undergo THA within 2 years would be helpful, but our knowledge, no such tool exists.(1) Are there preoperative intraoperative variables at time arthroscopy associated with subsequent THA? (2) Can these used develop predictive for THA?All patients undergoing from January 2009 through December 2011 were registered in longitudinal database. Inclusion criteria study group labral tear, eventually had THA. Patients compared control underwent tear did not during same period. Of 893 792 (88.7%) available followup minimum (mean, 31.1 ± 8.1 years) so considered this analysis. Multivariate regression analyses 41 performed. Using results multivariate regression, we developed simplified may helpful counseling regarding after arthroscopy.Variables simultaneously model older age (rate ratio, 1.06; 95% CI, 1.03-1.08; p < 0.0001), lower modified Harris score ratio [RR], 0.98; 0.96-0.99; = 0.0003), decreased femoral anteversion (RR, 0.97; 0.94-0.99; 0.0111), revision 2.4; 1.15-5.01; 0.0193), Outerbridge Grades II IV (Grade II: RR, 2.23 [95% 1.11-4.46], 0.023; Grade III: 2.17, 1.11-4.23], 0.024; IV: 2.96 1.34-6.52], 0.007), performance acetabuloplasty 1.83; 1.03-3.24; 0.038), lack osteoplasty 0.62; 0.36-1.06; 0.081). arthroscopy.Multiple factors have been identified as possible arthroscopy. weighted based on data is presented here useful predicting failure treatment. Determining best candidates remains challenging; careful attention long-term identifying characteristics successful outcomes should focus further study.Level III, therapeutic study.